[CAS NO. 629167-92-6] Mipomersen sodium
PRODUCTS SPECIFICATIONS [629167-92-6]
DESCRIPTION [629167-92-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 7595.00 |
| Molecular Formula | - |
| SMILES | [Mipomersen (sodium)] |
Summary
In Vitro
Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations
[2]
.
Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00231569 | Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc. |
Hypercholesterolemia
|
September 2005 | Phase 2 |
| NCT00280995 | Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc. |
Hypercholesterolemia, Familial
|
January 2006 | Phase 2 |
| NCT00281008 | Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc. |
Hypercholesterolemia, Familial
|
February 2006 | Phase 2 |
| NCT00216463 | Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc. |
Hypercholesterolemia
|
August 2005 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 13.17 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.1317 mL | 0.6583 mL | 1.3167 mL |
| 5 mM | 0.0263 mL | 0.1317 mL | 0.2633 mL |
| 10 mM | 0.0132 mL | 0.0658 mL | 0.1317 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (13.17 mM); Clear solution; Need ultrasonic
References